A Phase I Dose Escalation Study of Daily Oral OSI-930 in Patients With Advanced Solid Tumors.

Trial Profile

A Phase I Dose Escalation Study of Daily Oral OSI-930 in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Sep 2011

At a glance

  • Drugs OSI 930 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 May 2009 Planned end date changed from 1 Dec 2008 to 1 Sep 2009 as reported by ClinicalTrials.gov.
    • 17 Jul 2008 Status changed from recruiting to in progress, reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top